License: Creative Commons License Open Access by International Journal of Gerontology & Geriatric Research is licensed under a Creative Commons Attribution 4.0 International License. Based on a work at SciRes Literature..

Manuscript should be submitted in Word Document (.doc or .docx) through online form or can be mailed to the particular journal's E-mail ID or to submit@scireslit.com, scireslit@gmail.com

Articles

We publish a wide range of article types in the Medical and Clinical Groups.

Our Vision

SciRes Literature main aim is to enhance the importance of science and technology to the scientific community and also to provide an equal opportunity to seek and share ideas to all our researchers and scientists without any barriers to develop their career and helping in their development of discovering the world.

Author Feedback

Argilés Josep M

Argilés Josep M

Universitat de Barcelona, Spain

Professor Josep M. Argiles was born in Barcelona, Catalonia, Spain in 1956 and completed his undergraduate studies in Biology at the University of Barcelona graduating with a First Class Honours Degree and Special Prize for the best B.Sc. (1979).  In 1981 he received his Doctorate in Biochemistry from the same university with Cum Laude obtaining the Prize for the best doctorate of that year.  He then became Lecturer in Biochemistry and carried out postdoctoral work on acetone metabolism in mammals. In 1987 he undertook further postdoctoral training in the Laboratory of Metabolism and Molecular Biology at the National Institutes of Health, Bethesda, Maryland.  In 1988 he went to the Metabolic Research Laboratory, Radcliffe Infirmary, Oxford, UK to work on the metabolic effects of cytokines. He later became Full Professor of Biochemistry and Molecular Biology of Cancer at the Faculty of Biology, University of Barcelona being the leader of a research group interested in cancer cachexia. 
 
Prof. Argiles has authored and co-authored over 350 publications, including several books, many related to the field of cancer research. His department obtained the City of Barcelona Science Award in 1997. He has also filed several national and foreign –including U.S.—patents.  In addition to his research interests, Prof. Argiles has made many contributions to popular science, publishing dozens of articles as well as two books.  In 1985 he obtained the Divulga Prize for his contributions to popular science. He is an advisor of many research organizations including: European Union (DG XII), Wellcome Trust (United Kingdom),  Fundaçao de Amparo a Pesquisa do Estado de Såo Paolo, (Brasil), Austrian Science Foundation (Austria), Asociacion Française contre les Myopathies, (France), Killam Foundation (Canada). Natural Sciences and Engineering Research Council (Canada), Associacione Italiana per la Ricerca sul Cranco (Italy), Cancer Research UK (United Kingdom) FONICYT (Argentina),  Slovak Research and Development Agency  (Slovenia), Diabetes-UK (United Kingdom), The Natural Sciences and Engineering Research Council of Canada (NSERC) (Canadá) and  the Israel Science Foundation (Israel).  He reviews scientific articles for over 90 international journals.  He is also an active advisor of several pharmaceutical companies in the field of Medical Nutrition, participating in several clinical trials involving anti-cachectic molecules.
 
His main contribution to the field of cancer research concern the mechanisms associated with cancer cachexia.  Indeed, Prof. Argiles was the first scientist to describe the mechanism responsible for the increased protein breakdown in skeletal muscle of cancer patients which seems to be responsible for muscle wasting. He is responsible for the introduction of the concept of the cytokine balance of the cancer patient, the ratio of the pro-cachectic (TNF-, IL-6, IFN..) to anti-cachectic (IL-10, sTNFRs….) cytokines.  In addition to his work in describing mechanisms and mediators of cancer cachexia, Prof. Argiles has made interesting contributions in the form of pre-clinical studies regarding the pharmacological treatment of cachexia using different therapeutic startegies such as2-agonists or anabolic cytokines, such as IL-15.

  Authors submit all Proposals and manuscripts via Electronic Form! Submit a Manuscript!